Evaluation of liver transplant candidates with non-alcoholic steatohepatitis

Translational Gastroenterology and Hepatology

Volumn 7, Issue , 2022, Pages

  Esteban, James Philip G ^a,b   Asgharpour, Amon ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cardiac risk assessment; cirrhosis; end stage liver disease; liver transplantation (LT); Non alcoholic fatty liver disease (NAFLD); non alcoholic steatohepatitis (NASH); transplant evaluation

Indexed keywords

AGE; ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTRAST-ENHANCED ULTRASOUND; CORONARY ANGIOGRAPHY; DIABETES MELLITUS; DISEASE SURVEILLANCE; ECHOCARDIOGRAPHY; EXERCISE TEST; FRAILTY; FUNCTIONAL STATUS ASSESSMENT; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC STEATOHEPATITIS; NUTRITIONAL ASSESSMENT; OBESITY; PHYSIOLOGICAL STRESS; PORTAL VEIN THROMBOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOPENIA; SCREENING; SURGICAL RISK;

EID: 85131967777     PISSN: 2224476X     EISSN: 24151289     Source Type: Journal    
DOI: 10.21037/tgh.2020.03.04     Document Type: Review

References (192)

1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64:73-84.
2. Rinella ME. Nonalcoholic Fatty Liver Disease: A Systematic Review. JAMA 2015:313:2263-73.
3. Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67:123-33.
4. Younossi Z, Henry L. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. Gastroenterology 2016; 150:1778-85.
5. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865-73.
6. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017; 65:1557-65.
7. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413-9.
8. White DL, Kanwal F, El-Serag HB. Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review. Clin Gastroenterol Hepatol 2012; 10:1342-59.e2.
9. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148:547-55.
10. Cholankeril G, Wong RJ, Hu M, et al. Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci 2017; 62:2915-22.
11. Singal AK, Hasanin M, Kaif M, et al. Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous LiverKidney Transplantation in the United States. Transplantation 2016; 100:607-12.
12. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol 2019; 17:748-55.e3.
13. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59:2188-95.
14. Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 Annual Data Report: Liver. Am J Transplant 2018; 18:172-253.
15. O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008; 134:1764-76.
16. Martin P, DiMartini A, Feng S, et al. Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the AASLD and the American Society of Transplantation. Hepatology 2014; 59:1144-65.
17. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005; 5:307-13.
18. Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012; 18:29-37.
19. Su F, Yu L, Berry K, et al. Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. Gastroenterology 2016; 150:441-53.e6.
20. Aduen JF, Sujay B, Dickson RC, et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc 2009; 84:973-8.
21. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-56.
22. Lai JC, Sonnenday CJ, Tapper EB, et al. Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J Transplant 2019; 19:1896-906.
23. Tandon P, Tangri N, Thomas L, et al. A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients with Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale. Am J Gastroenterol 2016; 111:1759-67.
24. Lai JC, Volk ML, Strasburg D, et al. Performance-Based Measures Associate with Frailty in Patients with End-Stage Liver Disease. Transplantation 2016; 100:2656-60.
25. Lai JC, Feng S, Terrault NA, et al. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014; 14:1870-9.
26. Derck JE, Thelen AE, Cron DC, et al. Quality of life in liver transplant candidates: Frailty is a better indicator than severity of liver disease. Transplantation 2015; 99:340-4.
27. Dunn MA, Josbeno DA, Tevar AD, et al. Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization. Am J Gastroenterol 2016; 111:1768-75.
28. Tapper EB, Finkelstein D, Mittleman MA, et al. Standard Assessments of Frailty are Validated Predictors of Mortality in Hospitalized Patients with Cirrhosis. Hepatology 2015; 62:584-90.
29. Sinclair M, Poltavskiy E, Dodge JL, et al. Frailty is independently associated with increased hospitalization days in patients on the liver transplant waitlist. World J Gastroenterol 2017; 23:899-905.
30. Haugen CE, McAdams-DeMarco M, Holscher CM, et al. Multicenter Study of Age, Frailty and Waitlist Mortality Among Liver Transplant Candidates. Ann Surg 2020; 271:1132-6.
31. Bhanji RA, Narayanan P, Moynagh MR, et al. Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease. Liver Transpl 2019; 25:14-24.
32. Haugen CE, McAdams-DeMarco M, Verna EC, et al. Association Between Liver Transplant Wait-list Mortality and Frailty Based on Body Mass Index. JAMA Surg 2019; 154:1103-9.
33. Verna E, Chan C, Pisa J, et al. Frailty, physical performance and sarcopenia measures in patients awaiting liver transplantation predict mortality and post-operative complications. Am J Transplant 2014; 14:742.
34. Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl 2017; 23:1451-64.
35. Kim G, Kang SH, Kim MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS One 2017; 12:e0186990.
36. Montano-Loza AJ, Meza-Junco J, Baracos VE, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014; 20:640-8.
37. Carias S, Castellanos AL, Vilchez V, et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J Gastroenterol Hepatol 2016; 31:628-33.
38. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10:166-73.
39. Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant waitlist: its prevalence and independent prognostic value. Liver Transpl 2012; 18:1209-16.
40. Aby ES, Lee E, Saggi SS, et al. Pretransplant Sarcopenia in Patients with NASH Cirrhosis Does Not Impact Rehospitalization or Mortality. J Clin Gastroenterol 2019; 53:680-5.
41. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute / American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-8.
42. Wang X, Li J, Riaz DR, et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12:394-402.e1.
43. Kadayifci A, Tan V, Ursell PC, et al. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: A comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol 2008; 49:595-9.
44. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59:1410-5.
45. Younossi ZM, Stepanova M, Saab S, et al. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther 2014; 40:686-94.
46. Singhal A, Wilson GC, Wima K, et al. Impact of recipient morbid obesity on outcomes after liver transplantation. Transpl Int 2015; 28:148-55.
47. Kardashian AA, Dodge JL, Roberts J, et al. Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. Liver Int 2018; 38:553-63.
48. Segev DL, Thompson RE, Locke JE, et al. Prolonged waiting times for liver transplantation in obese patients. Ann Surg 2008; 248:863-70.
49. LaMattina JC, Foley DP, Fernandez LA, et al. Complications associated with liver transplantation in the obese recipient. Clin Transplant 2012; 26:910-8.
50. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35:105-9.
51. Dick AA, Spitzer AL, Seifert CF, et al. Liver transplantation at the extremes of the body mass index. Liver Transpl 2009; 15:968-77.
52. Leonard J, Heimbach JK, Malinchoc M, et al. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008; 8:667-72.
53. Bambha KM, Dodge JL, Gralla J, et al. Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: Risk modulated by model for end-stage liver disease. Liver Transpl 2015; 21:1286-94.
54. Wong RJ, Cheung R, Perumpail RB, et al. Diabetes mellitus, and not obesity, is associated with lower survival following liver transplantation. Dig Dis Sci 2015; 60:1036-44.
55. Saab S, Lalezari D, Pruthi P, et al. The impact of obesity on patient survival in liver transplant recipients: a metaanalysis. Liver Int 2015; 35:164-70.
56. Schlansky B, Naugler WE, Orloff SL, et al. Higher Mortality and Survival Benefit in Obese Patients Awaiting Liver Transplantation. Transplantation 2016; 100:2648-55.
57. Vanwagner LB, Bhave M, Te HS, et al. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012; 56:1741-50.
58. Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in subjects with non-alcoholic steatohepatitis. Clin J Am Soc Nephrol 2010; 5:2166-71.
59. Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11:e1001680.
60. VanWagner LB, Lapin B, Skari AI, et al. Impact of Renal Impairment on Cardiovascular Disease Mortality After Liver Transplantation for Nonalcoholic Steatohepatitis Cirrhosis. Liver Int 2015; 35:2575-83.
61. Organ Procurement and Transplantation Network. Policy 9: Allocation of Livers and Liver-Intestines. Effective date 10/24/2019.
62. Hmoud B, Kuo YF, Wiesner RH, et al. Outcomes of liver transplantation alone after listing for simultaneous kidney: comparison to simultaneous liver kidney transplantation. Transplantation 2015; 99:823-8.
63. Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?. J Hepatol 2018; 68:335-52.
64. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?. Atherosclerosis 2013; 230:258-67.
65. Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65:589-600.
66. Carey WD, Dumot JA, Pimentel RR, et al. The prevalence of coronary artery diseases in liver transplant candidates over age 50. Transplantation 1995; 59:859-64.
67. McAvoy NC, Kochar N, McKillop G, et al. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transpl 2008; 14:1725-31.
68. Wong VW, Wong GL, Yeung JC, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology 2016; 63:754-63.
69. Plotkin JS, Scott VL, Pinna A, et al. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996; 2:426-30.
70. Diedrich DA, Findlay JY, Harrison BA, et al. Influence of coronary artery disease on outcomes after liver transplantation. Transplant Proc 2008; 40:3554-7.
71. Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43:682-9.
72. Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57:1357-65.
73. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54:691-7.
74. Stine JG, Shah NL, Argo CK, et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl 2015; 21:1016-21.
75. Tripodi A, Fracanzani AL, Primignani M, et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol 2014; 61:148-54.
76. Yerdel MA, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000; 69:1873-81.
77. Agbim U, Jiang Y, Kedia SK, et al. Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients with Nonalcoholic Steatohepatitis. Liver Transpl 2019; 25:68-78.
78. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018; 155:1828-37.e2.
79. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9:428-33.
80. Leung C, Yeoh SW, Patrick D, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21:1189-96.
81. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-9.
82. Tsochatzis E, Coilly A, Nadalin S, et al. International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. Transplantation 2019; 103:45-56.
83. Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Int Med 2016; 165:305-15.
84. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387:679-90.
85. García-Compeán D, González-González JA, Lavalle-González FJ, et al. The treatment of diabetes mellitus of patients with chronic liver disease. Ann Hepatol 2015; 14:780-8.
86. Holmes G, Galitz L, Hu P, et al. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005; 60:469-76.
87. Henriksen JH, Fuglsang S, Bendtsen F, et al. Arterial hypertension in cirrhosis: arterial compliance, volume distribution, and central haemodynamics. Gut 2006; 55:380-7.
88. Malandris K, Paschos P, Katsoula A, et al. Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis. Ann Gastroenterol 2019; 32:287-97.
89. Goh GB, Pagadala MR, Dasarathy J, et al. Reninangiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int 2015; 35:979-85.
90. Loria P, Marchesini G, Nascimbeni F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis. 2014; 232:99-109.
91. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46:1453-63.
92. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376:1916-22.
93. Speliotes EK, Balakrishnan M, Friedman LS, et al. Treatment of Dyslipidemia in Common Liver Diseases. Clin Gastroenterol Hepatol 2018; 16:1189-96.
94. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014; 63:2985-3023.
95. Daniel K, Hause J, Osman F, et al. Liver transplant recipients with BMI 40 to <50 kg/m2 have excellent patient and graft survival. Hepatology 2019; 70:64A.
96. Spengler EK, O'Leary JG, Te HS, et al. Liver Transplantation in the Obese Cirrhotic Patient. Transplantation 2017; 101:2288-96.
97. Terjimanian MN, Harbaugh CM, Hussain A, et al. Abdominal Adiposity, Body Composition and Survival after Liver Transplantation. Clin Transplant 2016; 30:289-94.
98. Cornier MA, Despres JP, Davis N, et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation 2011; 124:1996-2019.
99. Kovesdy CP, Czira ME, Rudas A, et al. Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant 2010; 10:2644-51.
100. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149:367-78.
101. Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology 2017; 65:1293-305.
102. Heimbach JK, Watt KD, Poterucha JJ, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant 2013; 13:363-8.
103. European Association for the Study of the Liver (EASL)., European Association for the Study of Diabetes (EASD)., European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64:1388-402.
104. Lin MY, Tavakol MM, Sarin A, et al. Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates. Surg Obes Relat Dis 2013; 9:653-8.
105. Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9:897-901.
106. Zamora-Valdes D, Watt KD, Kellogg TA, et al. Longterm outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology 2018; 68:485-95.
107. Lin MY, Tavakol MM, Sarin A, et al. Safety and feasibility of sleeve gastrectomy in morbidly obese patients following liver transplantation. Surg Endosc 2013; 27:81-5.
108. Lazzati A, Iannelli A, Schneck AS, et al. Bariatric surgery and liver transplantation: a systematic review a new frontier for bariatric surgery. Obes Surg 2015; 25:134-42.
109. Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol 2012; 10:117-25.
110. Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis?. PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology 1996; 23:1041-6.
111. Huisman EJ, Trip EJ, Siersema PD, et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol 2011; 23:982-9.
112. Arora S, Mattina C, McAnenny C, et al. The development and validation of a nutritional prioritizing tool for use in patients with chronic liver disease. J Hepatol 2012; 56:S241.
113. Borhofen SM, Gerner C, Lehmann J, et al. The Royal Free Hospital-Nutritional Prioritizing Tool Is an Independent Predictor of Deterioration of Liver Function and Survival in Cirrhosis. Dig Dis Sci 2016; 61:1735-43.
114. Booi AN, Menendez J, Norton HJ, et al. Validation of a Screening Tool to Identify Undernutrition in Ambulatory Patients with Liver Cirrhosis. Nutr Clin Pract 2015; 30:683-9.
115. Tandon P, Raman M, Mourtzakis M, et al. A practical approach to nutritional screening and assessment in cirrhosis Hepatology 2017; 65:1044-57.
116. Carey EJ, Lai JC, Wang CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017; 23:625-33.
117. Masuda T, Shirabe K, Ikegami T, et al. Sarcopenia is a prognostic factor in living donor liver transplantation. Liver Transpl 2014; 20:401-7.
118. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and Post-Liver Transplant Mortality. J Am Coll Surg 2010; 211:271-8.
119. Krell RW, Kaul DR, Martin AR, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl 2013; 19:1396-402.
120. van Vugt JL, Levolger S, de Bruin RW, et al. Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation. Am J Transplant 2016; 16:2277-92.
121. Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic patients. Nutrition 2005; 21:113-7.
122. Carey EJ, Steidley DE, Aqel BA, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl 2010; 16:1373-8.
123. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, et al. Inclusion of Sarcopenia Within MELD (MELDSarcopenia) and the Prediction of Mortality in Patients With Cirrhosis. Clin Transl Gastroenterol 2015; 6:e102.
124. Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013; 58:325-36.
125. Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol 2012; 27:430-1.
126. Román E, Torrades MT, Nadal MJ, et al. Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis. Dig Dis Sci 2014; 59:1966-75.
127. Zenith L, Meena N, Ramadi A, et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12:1920-6.e2.
128. Duarte-Rojo A, Ruiz-Margain A, Montaño-Loza AJ, et al. Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list. Liver Transpl 2018; 24:122-39.
129. Ney M, Gramlich L, Mathiesen V, et al. Patient-perceived barriers to lifestyle interventions in cirrhosis. Saudi J Gastroenterol 2017; 23:97-104.
130. García-Pagàn JC, Santos C, Barbera JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996; 111:1300-6.
131. Macías-Rodríguez RU, Ilarraza-Lomelí H, Ruiz-Margáin A, et al. Changes in Hepatic Venous Pressure Gradient Induced by Physical Exercise in Cirrhosis: Results of a Pilot Randomized Open Clinical Trial. Clin Transl Gastroenterol 2016; 7:e180.
132. Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017; 66:564-74.
133. Samoylova ML, Covinsky KE, Haftek M, et al. Disability in patients with end-stage liver disease: Results from the functional assessment in liver transplantation study. Liver Transpl 2017; 23:292-8.
134. Orman ES, Ghabril M, Chalasani N. Poor Performance Status Is Associated With Increased Mortality in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2016; 14:1189-95.e1.
135. Lai JC, Dodge JL, Sen S, et al. Functional decline in patients with cirrhosis awaiting liver transplantation: Results from the functional assessment in liver transplantation (FrAILT) study. Hepatology 2016; 63:574-80.
136. VanWagner LB, Ning H, Allen NB, et al. Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2017; 153:1260-72.e3.
137. Hagström H, Nasr P, Ekstedt M, et al. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol 2017; 52:159-65.
138. Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012; 57:384-91.
139. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51:1972-8.
140. Luca A, Garcia-Pagan JC, Bosch J, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997; 112:1284-9.
141. Ajmera V, Belt P, Wilson LA, et al. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol 2018; 16:1511-20.e5.
142. Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015; 13:594-601.e1.
143. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33:1394-403.
144. Sinha J, Mehta N, Dodge JL, et al. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant?. Analysis of the All-Comers Protocol. Hepatology 2019; 70:1185-96.
145. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68:723-50.
146. Tzartzeva K, Obi J, Rich NE, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154:1706-17.e1.
147. Gopal P, Yopp AC, Waljee AK. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12:870-7.
148. Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol 2016; 65:1148-54.
149. Choi DT, Kum HC, Park S, et al. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2019; 17:976-87.e4.
150. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017; 45:169-77.
151. Andersson KL, Salomon JA, Goldie SJ, et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008; 6:1418-24.
152. Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MRI imaging - a systematic review and meta-analysis. Radiology 2015; 275:97-109.
153. Pocha C, Dieperink E, McMaken KA, et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - a randomised study. Aliment Pharmacol Ther 2013; 38:303-12.
154. Kim SY, An J, Lim YS, et al. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. JAMA Oncol 2017; 3:456-63.
155. Kim HL, An J, Park JA, et al. Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis. Hepatology 2019; 69:1599-613.
156. Marks RM, Ryan A, Heba ER, et al. Diagnostic perpatient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol 2015; 204:527-35.
157. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87:9-15.
158. Dec GW, Kondo N, Farrell ML, et al. Cardiovascular complications following liver transplantation. Clin Transplant 1995; 9:463-71.
159. Raval Z, Harinstein ME, Skaro AI, et al. Cardiovascular Risk Assessment of the Liver Transplant Candidate. J Am Coll Cardiol 2011; 58:223-31.
160. Canto JG, Kiefe Cim, Rogers WJ. Number of Coronary Heart Disease Risk Factors and Mortality in Patients With First Myocardial Infarction. JAMA 2011; 306:2120-7.
161. Josefsson A, Fu M, Björnsson E, et al. Prevalence of pretransplant electrocardiographic abnormalities and posttransplant cardiac events in patients with liver cirrhosis. BMC Gastroenterol 2014; 14:65.
162. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27:28-34.
163. Mohamed R, Forsey PR, Davies MK, et al. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996; 23:1128-34.
164. Garg A, Armstrong WF. Echocardiography in liver transplant candidates. JACC Cardiovasc Imaging 2013; 6:105-19.
165. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 53:e1-90.
166. Torregrosa M, Aguade S, Dos L, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42:68-74.
167. Bushyhead D, Kirkpatrick JN, Goldberg D. Pretransplant echocardiographic parameters as markers of posttransplant outcomes in liver transplant recipients. Liver Transpl 2016; 22:316-23.
168. Kia L, Shah SJ, Wang E, et al. Role of pretransplant echocardiographic evaluation in predicting outcomes following liver transplantation. Am J Transplant 2013; 13(9):2395-401.
169. Lima B, Nowicki ER, Miller CM, et al. Outcomes of simultaneous liver transplantation and elective cardiac surgical procedures. Ann Thorac Surg 2011; 92:1580-4.
170. Nicolau-Raducu R, Marshall T, Patel H, et al. Long-Term Cardiac Morbidity and Mortality in Patients with Aortic Valve Disease Following Liver Transplantation: A Case Matching Study. Semin Cardiothorac Vasc Anesth 2017; 21:345-51.
171. Adachi T, Murakawa M, Uetsuki N, Segawa H. Living related donor liver transplantation in a patient with severe aortic stenosis. Br J Anaesth 1999; 83:488-90.
172. Maraj S, Jacobs LE, Maraj R, et al. Inducible left ventricular outflow tract gradient during dobutamine stress echocardiography: an association with intraoperative hypotension but not a contraindication to liver transplantation. Echocardiography 2004; 21:681-5.
173. Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation 2016; 100:1440-52.
174. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461-8.
175. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000; 6:453-8.
176. Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996; 71:543-51.
177. Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6:443-50.
178. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2014; 130:2215-45.
179. Kong YG, Kang JW, Kim YK, et al. Preoperative coronary calcium score is predictive of early postoperative cardiovascular complications in liver transplant recipients. Br J Anaesth 2015; 114:437-43.
180. Jodocy D, Abbrederis S, Graziadei IW, et al. Coronary computer tomographic angiography for preoperative risk stratification in patients undergoing liver transplantation. Eur J Radiol 2012; 81:2260-4.
181. Yilmaz Y, Kurt R, Yonal O, et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Atherosclerosis 2010; 211:182-6.
182. Harinstein ME, Flaherty JD, Ansari AH, et al. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transplant 2008; 8:1523-8.
183. Davidson CJ, Gheorghiade M, Flaherty JD, et al. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am J Cardiol 2002; 89:359-60.
184. Bhutani S, Tobis J, Geovrgyan R, et al. Accuracy of Stress Myocardial Perfusion Imaging to Diagnose Coronary Artery Disease in End Stage Liver Disease Patients. Am J Cardiol 2013; 111:1057-61.
185. Konerman MA, Fritze D, Weinberg RL, et al. Incidence of and risk assessment for adverse cardiovascular outcomes after liver transplantation: a systematic review. Transplantation 2017; 101:1645-57.
186. Soldera J, Camazzola F, Rodríguez S, et al. Dobutamine stress echocardiography, myocardial perfusion scintigraphy, invasive coronary angiography, and postliver transplantation events: systematic review and metaanalysis. Clin Transplant 2018; 32:e13222.
187. Maddur H, Bourdillon PD, Liangpunsakul S, et al. Role of cardiac catheterization and percutaneous coronary intervention in the preoperative assessment and management of patients before orthotopic liver transplantation. Liver Transpl 2014; 20:664-72.
188. Sharma M, Yong C, Majure D, et al. Safety of Cardiac Catheterization in Patients With End-Stage Liver Disease Awaiting Liver Transplantation. Am J Cardiol 2009; 103:742-6.
189. Jacobs E, Singh V, Damluji A, et al. Safety of transradial cardiac catheterization in patients with end-stage liver disease. Catheter Cardiovasc Interv 2014; 83:360-6.
190. Axelrod D, Koffron A, Dewolf A, et al. Safety and efficacy of combined orthotopic liver transplantation and coronary artery bypass grafting. Liver Transpl 2004; 10:1386-90.
191. McFalls EO, Ward HB, Moritz TE, et al. Coronary-Artery Revascularization before Elective Major Vascular Surgery. N Engl J Med 2004; 351:2795-804.
192. VanWagner LB, Lapin B, Levitsky J, et al. High early cardiovascular mortality after liver transplantation. Liver Transpl 2014; 20:1306-16.